Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 9.12 CAD 2.47% Market Closed
Market Cap: CA$331m

Profound Medical Corp
Note Receivable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Profound Medical Corp
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Note Receivable
$300k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Note Receivable
CA$1m
CAGR 3-Years
450%
CAGR 5-Years
N/A
CAGR 10-Years
48%
MedMira Inc
XTSX:MIR
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurora Spine Corp
XTSX:ASG
Note Receivable
$253.9k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Ondine Biomedical Inc
LSE:OBI
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Conavi Medical Corp
XTSX:CNVI
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
331m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
3.42 CAD
Overvaluation 63%
Intrinsic Value
Price CA$9.12

See Also

What is Profound Medical Corp's Note Receivable?
Note Receivable
300k USD

Based on the financial report for Dec 31, 2025, Profound Medical Corp's Note Receivable amounts to 300k USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett